iX Biopharma — a visual brief on the FY2026 annual report

HealthcarePharmaceuticalsSGXCatalist

A specialty pharmaceutical company focused on sublingual drug delivery and nutraceuticals. This visual brief distils the annual report into its business model, financial highlights, cash flow quality, and the key risks worth understanding.

Buy Me a Coffee Back to Library

Want a company covered next?

Suggest a public company for a future OnePage Alpha visual brief. Requests help guide coverage, but do not influence conclusions.

Request a Company

Inside the brief

What this brief covers

Business model

What the company does and how it makes money.

Financial highlights

Revenue, profit, margins, and key operating numbers.

Cash flow quality

Whether accounting profit is supported by cash generation.

Accounting observations

Important notes, adjustments, and disclosure items.

Key risks

Business, funding, operational, and execution risks to monitor.

Questions for management

Practical questions investors can ask before going deeper.

Related briefs

Addvalue Technologies Ltd.

Singapore · Satellite Communications

Equity Research Snapshot: Addvalue Technologies Ltd. (SGX: A31)

A visual brief on Addvalue Technologies’ FY2026 reported turnaround, highlighting revenue growth, operating cash flow improvement, de-leveraging, order book visibility, customer concentration, capitalized development costs, and valuation/event-risk considerations.

Satellite CommunicationsTurnaroundCash FlowDe-leveragingCustomer ConcentrationAccounting ObservationsSGX

View Brief

SMPL · SGX15 Feb 2026

Sample Company Ltd.

Singapore · Industrials

Sample Company Ltd. — a visual brief on the FY2026 annual report

A placeholder entry showing how a company brief appears in the library. Duplicate this object, swap the details, and add your image and download file to publish a new visual brief.

IndustrialsSampleSGX

View Brief

Important disclaimer

OnePage Alpha is an educational research project. Content is based on public company disclosures and is provided for informational purposes only. Nothing on this site is financial advice, investment advice, or a recommendation to buy, sell, or hold any security. Readers should verify figures from original source documents and consult a licensed financial adviser where appropriate.